Recombinant mumps virus as a cancer therapeutic agent

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Mumps virus belongs to the family of Paramyxoviridae and has the potential to be an oncolytic agent. Mumps virus Urabe strain had been tested in the clinical setting as a treatment for human cancer four decades ago in Japan. These clinical studies demonstrated that mumps virus could be a promising cancer therapeutic agent that showed significant antitumor activity against various types of cancers. Since oncolytic virotherapy was not in the limelight until the beginning of the 21 st century, the interest to pursue mumps virus for cancer treatment slowly faded away. Recent success stories of oncolytic clinical trials prompted us to resurrect the mumps virus and to explore its potential for cancer treatment. We have obtained the Urabe strain of mumps virus from Osaka University, Japan, which was used in the earlier human clinical trials. In this report we describe the development of a reverse genetics system from a major isolate of this Urabe strain mumps virus stock, and the construction and characterization of several recombinant mumps viruses with additional transgenes. We present initial data demonstrating these recombinant mumps viruses have oncolytic activity against tumor cell lines in vitro and some efficacy in preliminary pilot animal tumor models.

Original languageEnglish (US)
Article number16019
JournalMolecular Therapy - Oncolytics
Volume3
DOIs
StatePublished - Aug 10 2016

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Recombinant mumps virus as a cancer therapeutic agent'. Together they form a unique fingerprint.

  • Cite this